Study yields promising results for skin infection drug

12/21/2012 | Reuters

The antibiotic oritavancin performed comparably with standard-of-care vancomycin in terms of efficacy, according to findings from a late-stage trial. The drug met the primary endpoint of the study, which was to halt the spread of the infection and to eliminate fever. The drug was tested for the treatment of acute bacterial skin and skin structure infections by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY